Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (epicardial cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: iptacopan, iptacopan hydrochloride | 0.90 |
| trials ClinicalTrials.gov | 5 Parkinson's trials, 1 stopped | 0.84 |
| literature PubMed | 9 Parkinson's papers of 1,757 | 0.70 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 12209
Sealed predictions
- CFB in dopamine neurons, braak-0.27 (p 0.474) → -0.06 (p 0.873)receipt 12216
Swarm cases
receipt 12216: CFB in dopamine neurons, braak
- power
- full sample -0.16 (p 0.526, n 18), 95% CI -0.58 to +0.33. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.17 (p 0.498, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.50 (p 0.033, n 18). not the mix.
- skeptic
- leave-one-out range -0.30 to -0.06, sign flips 0; without severely affected donors -0.16 (p 0.526, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CFB in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts